explore -WSS

explore

author：hotspot 2025-09-27 12:47:37 - browse：25

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Medicare drug price negotiation’s day in court

WSS

Vertex non

How to fix the rural physician shortage in the U.S.

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Time to name cancers by genetics, not organ of origin, expert says

Quicker fix for pulse oximeters urged during FDA public meeting

SAMSHA loosens regulations on methadone treatment centers

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Medicare drug price negotiation’s day in court

Duchenne breakthrough therapy leaves behind pioneering families

Flu vaccine offering decent levels of protection this winter, new data show

Medicare proposal to cover medical devices draws a mixed reaction

Flu vaccine offering decent levels of protection this winter, new data show

Walensky prepares to leave CDC — and Congress — behind

SAMSHA loosens regulations on methadone treatment centers

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Novo Nordisk to expand supply of Wegovy for U.S. patients

focus

Biden administration opens offers in Medicare drug price negotiations

ALS groups 'won't be played again' by the FDA, drug sponsors

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Juul spent big to court Black leaders to promote its e

Change Healthcare cyberattack outage could last weeks

AstraZeneca loses challenge to Medicare drug price negotiation

Wikipedia

explore

focus

explore